153 -5 (67) 2024 - Rаkhimov R.А., Pereyaslov D.I. - CHARACTERISATION OF THE FIRST POST-PANDEMIC SEASON OF INFLUENZA AND ARI OF 2023-2024 IN TASHKENT

CHARACTERISATION OF THE FIRST POST-PANDEMIC SEASON OF INFLUENZA AND ARI OF 2023-2024 IN TASHKENT

Rаkhimov R.А. - The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Pereyaslov D.I. - The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Ibadullaeva N.S. - The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Ruzmetova S.I. - The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Rаkhimov R.R. - The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Rasulova D.M. - The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Resume

To determine the nature and etiological structure of the morbidity of influenza and other acute respiratory infections in the postpandemic period, the weekly total morbidity of influenza and acute respiratory infections in the season 2023-2024 in Tashkent city was analyzed and 140 patients were selectively examined by PCR method. The epidemic period lasted for 10 weeks (41-50 weeks). The highest incidence was in children 0-2 years and 3-6 years. Acute respiratory viral infection was confirmed in 69.3%. SARS-CoV-2 was detected in 29.6%, influenza A in 28.7%, respiratory syncytial virus in 23.2%, bocavirus in 11.1%, and adenovirus in 7.4%.

Key words: SARS-CoV-2, influenza, respiratory syncytial virus, bocavirus, adenovirus, epidemiology, etiology.

First page

870

Last page

874

For citation:Rаkhimov R.А., Pereyaslov D.I., Ibadullaeva N.S., Ruzmetova S.I., Rаkhimov R.R., Rasulova D.M. - CHARACTERISATION OF THE FIRST POST-PANDEMIC SEASON OF INFLUENZA AND ARI OF 2023-2024 IN TASHKENT//New Day in Medicine 5(67)2024 870-874 https://newdayworldmedicine.com/en/article/3758

List of References

1. Breaking COVID-19 global health emergency is over. 5 мая 2023 г. https://twitter.com/WHO/status/1654477139620638722.
2. Stamm, P., Sagoschen, I., Weise, K. et al. Influenza and RSV incidence during COVID-19 pandemic-an observational study from in-hospital point-of-care testing // Med Microbiol Immunol. – 2021;210. – Р.277–282. https://doi.org/10.1007/s00430-021-00720-7
3. Lu Y., Wang Y., Shen C., Luo J., Yu W. Decreased Incidence of Influenza During the COVID-19 Pandemic // International Journal of General Medicine, 14 March 2022 Volume 2022;15. - P.2957-2962. https://doi.org/10.2147/IJGM.S343940.
4. Рахимов Р.А. Эпидемические пороги заболеваемости гриппом и ОРИ для г. Ташкента на сезон 2019-2020 гг. // Информационное письмо НИИ Вирусологии МЗ РУз. Ташкент - 2019. - 3с.
5. Рахимов Р.А., Ибадуллаева Н.С., Рахимов Р.Р., Джемилева С.Ф. Плешков Б.А. Характеристика заболеваемости гриппом и ОРИ в сезон 2017-2018 гг. // Медицинский журнал Узбекистана. Ташкент, 2018. - №4. - С.41-44.
6. Рахимов Р.А., Ибадуллаева Н.С., Рахимов Р.Р., Джемилева С.Ф., Плешков Б.А. Характеритика заболеваемости гриппом и ОРИ в сезон 2018-2019 гг. // Инфекция, иммунитет и фармакология. Ташкент, 2019. - №5. - С.198-202.
7. WHO COVID-19 dashboard. https://data.who.int/dashboards/covid19/cases/n=c.
8. https://www.who.int/europe/ru/news/item/09-10-2023-vulnerable--vaccinate.-protecting-the-unprotected-from-covid-19-and-influenza.
9. Vekemans J., Moorthy V., Giersing B., Friede M., Hombach J., Arora N, Modjarrad K., Smith PG., Karron R., Graham B., Kaslow DC. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics // Vaccine. 2019 Nov 28;37(50):7394-7395. doi: 10.1016/j.vaccine.2017.09.092.
10. Sparrow E., Adetifa I., Chaiyakunapruk N., Cherian T., Fell DB., Graham BS., Innis B., Kaslow DC., Karron RA., Nair H., Neuzil KM., Saha S., Smith PG., Srikantiah P., Were F., Zar HJ., Feikin D. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use // Vaccine. 2022 Jun 9;40(26):3506-3510. doi: 10.1016/j.vaccine.2022.02.040.

    file

    download